Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report

Thierry Alcindor; Sungmi Jung; Lucy Gilbert

doi:10.3390/curroncol28030199

Current Oncology (Jun 2021)

Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report

Thierry Alcindor,
Sungmi Jung,
Lucy Gilbert

Affiliations

Thierry Alcindor: Cedars Cancer Center, Division of Medical Oncology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada
Sungmi Jung: Department of Pathology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada
Lucy Gilbert: Cedars Cancer Center, Division of Gynecologic Oncology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada

DOI: https://doi.org/10.3390/curroncol28030199
Journal volume & issue: Vol. 28, no. 3
pp. 2146 – 2149

Abstract

Read online

A 32-year-old woman with chemorefractory mullerian adenosarcoma showed clinical benefit in response to administration of lenvatinib plus pembrolizumab. In this case report, we describe the course of her illness and her response to this treatment.

Published in Current Oncology

ISSN: 1198-0052 (Print); 1718-7729 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/curroncol

About the journal

Abstract

Keywords